Encorafenib Use, Prophylaxis, and Safety Management in BRAF V600E–Mutated CRC

Authored by Eric Kowalchyk, published on 2026-10-19 22:47:47.0

The algorithm is broadly aligned with current U.S. practice: first-line encorafenib plus cetuximab with mFOLFOX6 or FOLFIRI is FDA-approved, and encorafenib plus cetuximab remains supported after prior therapy. Dosing, reproductive counseling, interaction management, and most cetuximab infusion-reaction and encorafenib dose-modification instructions track current prescribing information. Several toxicity branches require refinement because cetuximab electrolytes should be monitored weekly, bullous reactions should trigger urgent evaluation rather than routine rash management, and management of uveitis, hemorrhage, QT prolongation, and grade 4 toxicity depends on severity and recurrence.

  1. Confirm Metastatic CRC With BRAF V600E Mutation
    Current labeling requires metastatic CRC with a BRAF V600E mutation detected by an FDA-authorized test before encorafenib-based treatment.
    • Has the Patient Received Prior Metastatic Therapy?
      • Plan First-Line Encorafenib With Cetuximab Plus mFOLFOX6 or FOLFIRI
        BREAKWATER established first-line benefit with mFOLFOX6 and subsequently with FOLFIRI; the FDA granted traditional approval for encorafenib-cetuximab with fluorouracil-based chemotherapy in February 2026.
        • Obtain CBC, CMP, Electrolytes, Skin Examination; ECG if QT Risk
          • Is the Patient of Reproductive Potential?
            • Verify Pregnancy Status: Is Pregnancy Confirmed?
              • Pregnancy Confirmed → Do Not Initiate Until Multidisciplinary Risk–Benefit Review
              • Counsel on Effective Nonhormonal Contraception
                • Is a Correctable Pretreatment Risk Present?
                  • Delay Treatment; Correct Electrolytes, Mitigate QT Risk, and Modify CYP3A4-Interacting Drugs
                    • Start Moisturizer, SPF ≥30, Hydrocortisone 1%, and Doxycycline 100 mg BID for 6–8 Weeks
                      A moisturizer, sunscreen, topical corticosteroid, and oral tetracycline constitute a widely used preemptive EGFR-inhibitor skin regimen. The landmark randomized evidence used panitumumab, so applying the exact regimen to cetuximab is class-based extrapolation; sunscreen alone has not shown clear preventive benefit.
                      • Premedicate With IV H1 Antagonist 30–60 Minutes Before Initial Cetuximab; Give Chemotherapy Antiemetics
                        • Start Encorafenib 300 mg Orally Once Daily With Selected Regimen
                          Three hundred milligrams orally once daily is the approved encorafenib dose with cetuximab, including chemotherapy-containing CRC regimens.
                          • Each Cycle: Monitor Labs, Rash, GI Toxicity, Bleeding; ECG if Risk; Skin Exam Every Two Months
                            • Has Clinically Significant Toxicity Developed?
                              • Continue Until Progression or Unacceptable Toxicity
                              • Classify Toxicity and Identify the Likely Causative Agent
                                • What Is the Dermatologic Toxicity Severity?
                                  • Continue Therapy; Intensify Topical Corticosteroid and Doxycycline; Culture Suspected Superinfection
                                  • Hold Cetuximab 1–2 Weeks; Continue Tetracycline, Intensify Topical Therapy, and Obtain Dermatology Review
                                • Continue for Grade 1–2 GI Toxicity; Add Antiemetic, Loperamide, Hydration, and Exclude Infection
                                • Hold Encorafenib Up to Four Weeks; Resume at 225 mg, Then 150 mg for Recurrent Toxicity
                                  • Permanently Discontinue Encorafenib if 150 mg Daily Remains Intolerable
                                • Hold Encorafenib; Urgently Evaluate Uveitis, Major Hemorrhage, QTcF >500 ms, or Grade 4 Toxicity
                                  Urgent evaluation is appropriate, but this combined node is only partially aligned with the label. Uveitis, hemorrhage, QTcF above 500 ms, and grade 4 toxicity have different rules, and some circumstances require immediate permanent discontinuation rather than a simple hold.
                                • What Is the Cetuximab Infusion-Reaction Grade?
                                  • Grade 1–2: Pause Infusion, Treat Symptoms, Then Resume at Half the Infusion Rate
                                  • Grade 3–4: Stop Infusion, Treat Immediately, and Permanently Discontinue Cetuximab
                                    • Continue Encorafenib With mFOLFOX6/FOLFIRI; Stop if Chemotherapy Stops or Was Not Used
                  • Start Moisturizer, SPF ≥30, Hydrocortisone 1%, and Doxycycline 100 mg BID for 6–8 Weeks
                    A moisturizer, sunscreen, topical corticosteroid, and oral tetracycline constitute a widely used preemptive EGFR-inhibitor skin regimen. The landmark randomized evidence used panitumumab, so applying the exact regimen to cetuximab is class-based extrapolation; sunscreen alone has not shown clear preventive benefit.
                    • Premedicate With IV H1 Antagonist 30–60 Minutes Before Initial Cetuximab; Give Chemotherapy Antiemetics
                      • Start Encorafenib 300 mg Orally Once Daily With Selected Regimen
                        Three hundred milligrams orally once daily is the approved encorafenib dose with cetuximab, including chemotherapy-containing CRC regimens.
                        • Each Cycle: Monitor Labs, Rash, GI Toxicity, Bleeding; ECG if Risk; Skin Exam Every Two Months
                          • Has Clinically Significant Toxicity Developed?
                            • Continue Until Progression or Unacceptable Toxicity
                            • Classify Toxicity and Identify the Likely Causative Agent
                              • What Is the Dermatologic Toxicity Severity?
                                • Continue Therapy; Intensify Topical Corticosteroid and Doxycycline; Culture Suspected Superinfection
                                • Hold Cetuximab 1–2 Weeks; Continue Tetracycline, Intensify Topical Therapy, and Obtain Dermatology Review
                              • Continue for Grade 1–2 GI Toxicity; Add Antiemetic, Loperamide, Hydration, and Exclude Infection
                              • Hold Encorafenib Up to Four Weeks; Resume at 225 mg, Then 150 mg for Recurrent Toxicity
                                • Permanently Discontinue Encorafenib if 150 mg Daily Remains Intolerable
                              • Hold Encorafenib; Urgently Evaluate Uveitis, Major Hemorrhage, QTcF >500 ms, or Grade 4 Toxicity
                                Urgent evaluation is appropriate, but this combined node is only partially aligned with the label. Uveitis, hemorrhage, QTcF above 500 ms, and grade 4 toxicity have different rules, and some circumstances require immediate permanent discontinuation rather than a simple hold.
                              • What Is the Cetuximab Infusion-Reaction Grade?
                                • Grade 1–2: Pause Infusion, Treat Symptoms, Then Resume at Half the Infusion Rate
                                • Grade 3–4: Stop Infusion, Treat Immediately, and Permanently Discontinue Cetuximab
                                  • Continue Encorafenib With mFOLFOX6/FOLFIRI; Stop if Chemotherapy Stops or Was Not Used
            • Is a Correctable Pretreatment Risk Present?
              • Delay Treatment; Correct Electrolytes, Mitigate QT Risk, and Modify CYP3A4-Interacting Drugs
                • Start Moisturizer, SPF ≥30, Hydrocortisone 1%, and Doxycycline 100 mg BID for 6–8 Weeks
                  A moisturizer, sunscreen, topical corticosteroid, and oral tetracycline constitute a widely used preemptive EGFR-inhibitor skin regimen. The landmark randomized evidence used panitumumab, so applying the exact regimen to cetuximab is class-based extrapolation; sunscreen alone has not shown clear preventive benefit.
                  • Premedicate With IV H1 Antagonist 30–60 Minutes Before Initial Cetuximab; Give Chemotherapy Antiemetics
                    • Start Encorafenib 300 mg Orally Once Daily With Selected Regimen
                      Three hundred milligrams orally once daily is the approved encorafenib dose with cetuximab, including chemotherapy-containing CRC regimens.
                      • Each Cycle: Monitor Labs, Rash, GI Toxicity, Bleeding; ECG if Risk; Skin Exam Every Two Months
                        • Has Clinically Significant Toxicity Developed?
                          • Continue Until Progression or Unacceptable Toxicity
                          • Classify Toxicity and Identify the Likely Causative Agent
                            • What Is the Dermatologic Toxicity Severity?
                              • Continue Therapy; Intensify Topical Corticosteroid and Doxycycline; Culture Suspected Superinfection
                              • Hold Cetuximab 1–2 Weeks; Continue Tetracycline, Intensify Topical Therapy, and Obtain Dermatology Review
                            • Continue for Grade 1–2 GI Toxicity; Add Antiemetic, Loperamide, Hydration, and Exclude Infection
                            • Hold Encorafenib Up to Four Weeks; Resume at 225 mg, Then 150 mg for Recurrent Toxicity
                              • Permanently Discontinue Encorafenib if 150 mg Daily Remains Intolerable
                            • Hold Encorafenib; Urgently Evaluate Uveitis, Major Hemorrhage, QTcF >500 ms, or Grade 4 Toxicity
                              Urgent evaluation is appropriate, but this combined node is only partially aligned with the label. Uveitis, hemorrhage, QTcF above 500 ms, and grade 4 toxicity have different rules, and some circumstances require immediate permanent discontinuation rather than a simple hold.
                            • What Is the Cetuximab Infusion-Reaction Grade?
                              • Grade 1–2: Pause Infusion, Treat Symptoms, Then Resume at Half the Infusion Rate
                              • Grade 3–4: Stop Infusion, Treat Immediately, and Permanently Discontinue Cetuximab
                                • Continue Encorafenib With mFOLFOX6/FOLFIRI; Stop if Chemotherapy Stops or Was Not Used
              • Start Moisturizer, SPF ≥30, Hydrocortisone 1%, and Doxycycline 100 mg BID for 6–8 Weeks
                A moisturizer, sunscreen, topical corticosteroid, and oral tetracycline constitute a widely used preemptive EGFR-inhibitor skin regimen. The landmark randomized evidence used panitumumab, so applying the exact regimen to cetuximab is class-based extrapolation; sunscreen alone has not shown clear preventive benefit.
                • Premedicate With IV H1 Antagonist 30–60 Minutes Before Initial Cetuximab; Give Chemotherapy Antiemetics
                  • Start Encorafenib 300 mg Orally Once Daily With Selected Regimen
                    Three hundred milligrams orally once daily is the approved encorafenib dose with cetuximab, including chemotherapy-containing CRC regimens.
                    • Each Cycle: Monitor Labs, Rash, GI Toxicity, Bleeding; ECG if Risk; Skin Exam Every Two Months
                      • Has Clinically Significant Toxicity Developed?
                        • Continue Until Progression or Unacceptable Toxicity
                        • Classify Toxicity and Identify the Likely Causative Agent
                          • What Is the Dermatologic Toxicity Severity?
                            • Continue Therapy; Intensify Topical Corticosteroid and Doxycycline; Culture Suspected Superinfection
                            • Hold Cetuximab 1–2 Weeks; Continue Tetracycline, Intensify Topical Therapy, and Obtain Dermatology Review
                          • Continue for Grade 1–2 GI Toxicity; Add Antiemetic, Loperamide, Hydration, and Exclude Infection
                          • Hold Encorafenib Up to Four Weeks; Resume at 225 mg, Then 150 mg for Recurrent Toxicity
                            • Permanently Discontinue Encorafenib if 150 mg Daily Remains Intolerable
                          • Hold Encorafenib; Urgently Evaluate Uveitis, Major Hemorrhage, QTcF >500 ms, or Grade 4 Toxicity
                            Urgent evaluation is appropriate, but this combined node is only partially aligned with the label. Uveitis, hemorrhage, QTcF above 500 ms, and grade 4 toxicity have different rules, and some circumstances require immediate permanent discontinuation rather than a simple hold.
                          • What Is the Cetuximab Infusion-Reaction Grade?
                            • Grade 1–2: Pause Infusion, Treat Symptoms, Then Resume at Half the Infusion Rate
                            • Grade 3–4: Stop Infusion, Treat Immediately, and Permanently Discontinue Cetuximab
                              • Continue Encorafenib With mFOLFOX6/FOLFIRI; Stop if Chemotherapy Stops or Was Not Used
      • Plan Encorafenib With Weekly Cetuximab
        The previously treated doublet is supported by BEACON CRC and current labeling, including the weekly cetuximab schedule.
        • Obtain CBC, CMP, Electrolytes, Skin Examination; ECG if QT Risk
          • Is the Patient of Reproductive Potential?
            • Verify Pregnancy Status: Is Pregnancy Confirmed?
              • Pregnancy Confirmed → Do Not Initiate Until Multidisciplinary Risk–Benefit Review
              • Counsel on Effective Nonhormonal Contraception
                • Is a Correctable Pretreatment Risk Present?
                  • Delay Treatment; Correct Electrolytes, Mitigate QT Risk, and Modify CYP3A4-Interacting Drugs
                    • Start Moisturizer, SPF ≥30, Hydrocortisone 1%, and Doxycycline 100 mg BID for 6–8 Weeks
                      A moisturizer, sunscreen, topical corticosteroid, and oral tetracycline constitute a widely used preemptive EGFR-inhibitor skin regimen. The landmark randomized evidence used panitumumab, so applying the exact regimen to cetuximab is class-based extrapolation; sunscreen alone has not shown clear preventive benefit.
                      • Premedicate With IV H1 Antagonist 30–60 Minutes Before Initial Cetuximab; Give Chemotherapy Antiemetics
                        • Start Encorafenib 300 mg Orally Once Daily With Selected Regimen
                          Three hundred milligrams orally once daily is the approved encorafenib dose with cetuximab, including chemotherapy-containing CRC regimens.
                          • Each Cycle: Monitor Labs, Rash, GI Toxicity, Bleeding; ECG if Risk; Skin Exam Every Two Months
                            • Has Clinically Significant Toxicity Developed?
                              • Continue Until Progression or Unacceptable Toxicity
                              • Classify Toxicity and Identify the Likely Causative Agent
                                • What Is the Dermatologic Toxicity Severity?
                                  • Continue Therapy; Intensify Topical Corticosteroid and Doxycycline; Culture Suspected Superinfection
                                  • Hold Cetuximab 1–2 Weeks; Continue Tetracycline, Intensify Topical Therapy, and Obtain Dermatology Review
                                • Continue for Grade 1–2 GI Toxicity; Add Antiemetic, Loperamide, Hydration, and Exclude Infection
                                • Hold Encorafenib Up to Four Weeks; Resume at 225 mg, Then 150 mg for Recurrent Toxicity
                                  • Permanently Discontinue Encorafenib if 150 mg Daily Remains Intolerable
                                • Hold Encorafenib; Urgently Evaluate Uveitis, Major Hemorrhage, QTcF >500 ms, or Grade 4 Toxicity
                                  Urgent evaluation is appropriate, but this combined node is only partially aligned with the label. Uveitis, hemorrhage, QTcF above 500 ms, and grade 4 toxicity have different rules, and some circumstances require immediate permanent discontinuation rather than a simple hold.
                                • What Is the Cetuximab Infusion-Reaction Grade?
                                  • Grade 1–2: Pause Infusion, Treat Symptoms, Then Resume at Half the Infusion Rate
                                  • Grade 3–4: Stop Infusion, Treat Immediately, and Permanently Discontinue Cetuximab
                                    • Continue Encorafenib With mFOLFOX6/FOLFIRI; Stop if Chemotherapy Stops or Was Not Used
                  • Start Moisturizer, SPF ≥30, Hydrocortisone 1%, and Doxycycline 100 mg BID for 6–8 Weeks
                    A moisturizer, sunscreen, topical corticosteroid, and oral tetracycline constitute a widely used preemptive EGFR-inhibitor skin regimen. The landmark randomized evidence used panitumumab, so applying the exact regimen to cetuximab is class-based extrapolation; sunscreen alone has not shown clear preventive benefit.
                    • Premedicate With IV H1 Antagonist 30–60 Minutes Before Initial Cetuximab; Give Chemotherapy Antiemetics
                      • Start Encorafenib 300 mg Orally Once Daily With Selected Regimen
                        Three hundred milligrams orally once daily is the approved encorafenib dose with cetuximab, including chemotherapy-containing CRC regimens.
                        • Each Cycle: Monitor Labs, Rash, GI Toxicity, Bleeding; ECG if Risk; Skin Exam Every Two Months
                          • Has Clinically Significant Toxicity Developed?
                            • Continue Until Progression or Unacceptable Toxicity
                            • Classify Toxicity and Identify the Likely Causative Agent
                              • What Is the Dermatologic Toxicity Severity?
                                • Continue Therapy; Intensify Topical Corticosteroid and Doxycycline; Culture Suspected Superinfection
                                • Hold Cetuximab 1–2 Weeks; Continue Tetracycline, Intensify Topical Therapy, and Obtain Dermatology Review
                              • Continue for Grade 1–2 GI Toxicity; Add Antiemetic, Loperamide, Hydration, and Exclude Infection
                              • Hold Encorafenib Up to Four Weeks; Resume at 225 mg, Then 150 mg for Recurrent Toxicity
                                • Permanently Discontinue Encorafenib if 150 mg Daily Remains Intolerable
                              • Hold Encorafenib; Urgently Evaluate Uveitis, Major Hemorrhage, QTcF >500 ms, or Grade 4 Toxicity
                                Urgent evaluation is appropriate, but this combined node is only partially aligned with the label. Uveitis, hemorrhage, QTcF above 500 ms, and grade 4 toxicity have different rules, and some circumstances require immediate permanent discontinuation rather than a simple hold.
                              • What Is the Cetuximab Infusion-Reaction Grade?
                                • Grade 1–2: Pause Infusion, Treat Symptoms, Then Resume at Half the Infusion Rate
                                • Grade 3–4: Stop Infusion, Treat Immediately, and Permanently Discontinue Cetuximab
                                  • Continue Encorafenib With mFOLFOX6/FOLFIRI; Stop if Chemotherapy Stops or Was Not Used
            • Is a Correctable Pretreatment Risk Present?
              • Delay Treatment; Correct Electrolytes, Mitigate QT Risk, and Modify CYP3A4-Interacting Drugs
                • Start Moisturizer, SPF ≥30, Hydrocortisone 1%, and Doxycycline 100 mg BID for 6–8 Weeks
                  A moisturizer, sunscreen, topical corticosteroid, and oral tetracycline constitute a widely used preemptive EGFR-inhibitor skin regimen. The landmark randomized evidence used panitumumab, so applying the exact regimen to cetuximab is class-based extrapolation; sunscreen alone has not shown clear preventive benefit.
                  • Premedicate With IV H1 Antagonist 30–60 Minutes Before Initial Cetuximab; Give Chemotherapy Antiemetics
                    • Start Encorafenib 300 mg Orally Once Daily With Selected Regimen
                      Three hundred milligrams orally once daily is the approved encorafenib dose with cetuximab, including chemotherapy-containing CRC regimens.
                      • Each Cycle: Monitor Labs, Rash, GI Toxicity, Bleeding; ECG if Risk; Skin Exam Every Two Months
                        • Has Clinically Significant Toxicity Developed?
                          • Continue Until Progression or Unacceptable Toxicity
                          • Classify Toxicity and Identify the Likely Causative Agent
                            • What Is the Dermatologic Toxicity Severity?
                              • Continue Therapy; Intensify Topical Corticosteroid and Doxycycline; Culture Suspected Superinfection
                              • Hold Cetuximab 1–2 Weeks; Continue Tetracycline, Intensify Topical Therapy, and Obtain Dermatology Review
                            • Continue for Grade 1–2 GI Toxicity; Add Antiemetic, Loperamide, Hydration, and Exclude Infection
                            • Hold Encorafenib Up to Four Weeks; Resume at 225 mg, Then 150 mg for Recurrent Toxicity
                              • Permanently Discontinue Encorafenib if 150 mg Daily Remains Intolerable
                            • Hold Encorafenib; Urgently Evaluate Uveitis, Major Hemorrhage, QTcF >500 ms, or Grade 4 Toxicity
                              Urgent evaluation is appropriate, but this combined node is only partially aligned with the label. Uveitis, hemorrhage, QTcF above 500 ms, and grade 4 toxicity have different rules, and some circumstances require immediate permanent discontinuation rather than a simple hold.
                            • What Is the Cetuximab Infusion-Reaction Grade?
                              • Grade 1–2: Pause Infusion, Treat Symptoms, Then Resume at Half the Infusion Rate
                              • Grade 3–4: Stop Infusion, Treat Immediately, and Permanently Discontinue Cetuximab
                                • Continue Encorafenib With mFOLFOX6/FOLFIRI; Stop if Chemotherapy Stops or Was Not Used
              • Start Moisturizer, SPF ≥30, Hydrocortisone 1%, and Doxycycline 100 mg BID for 6–8 Weeks
                A moisturizer, sunscreen, topical corticosteroid, and oral tetracycline constitute a widely used preemptive EGFR-inhibitor skin regimen. The landmark randomized evidence used panitumumab, so applying the exact regimen to cetuximab is class-based extrapolation; sunscreen alone has not shown clear preventive benefit.
                • Premedicate With IV H1 Antagonist 30–60 Minutes Before Initial Cetuximab; Give Chemotherapy Antiemetics
                  • Start Encorafenib 300 mg Orally Once Daily With Selected Regimen
                    Three hundred milligrams orally once daily is the approved encorafenib dose with cetuximab, including chemotherapy-containing CRC regimens.
                    • Each Cycle: Monitor Labs, Rash, GI Toxicity, Bleeding; ECG if Risk; Skin Exam Every Two Months
                      • Has Clinically Significant Toxicity Developed?
                        • Continue Until Progression or Unacceptable Toxicity
                        • Classify Toxicity and Identify the Likely Causative Agent
                          • What Is the Dermatologic Toxicity Severity?
                            • Continue Therapy; Intensify Topical Corticosteroid and Doxycycline; Culture Suspected Superinfection
                            • Hold Cetuximab 1–2 Weeks; Continue Tetracycline, Intensify Topical Therapy, and Obtain Dermatology Review
                          • Continue for Grade 1–2 GI Toxicity; Add Antiemetic, Loperamide, Hydration, and Exclude Infection
                          • Hold Encorafenib Up to Four Weeks; Resume at 225 mg, Then 150 mg for Recurrent Toxicity
                            • Permanently Discontinue Encorafenib if 150 mg Daily Remains Intolerable
                          • Hold Encorafenib; Urgently Evaluate Uveitis, Major Hemorrhage, QTcF >500 ms, or Grade 4 Toxicity
                            Urgent evaluation is appropriate, but this combined node is only partially aligned with the label. Uveitis, hemorrhage, QTcF above 500 ms, and grade 4 toxicity have different rules, and some circumstances require immediate permanent discontinuation rather than a simple hold.
                          • What Is the Cetuximab Infusion-Reaction Grade?
                            • Grade 1–2: Pause Infusion, Treat Symptoms, Then Resume at Half the Infusion Rate
                            • Grade 3–4: Stop Infusion, Treat Immediately, and Permanently Discontinue Cetuximab
                              • Continue Encorafenib With mFOLFOX6/FOLFIRI; Stop if Chemotherapy Stops or Was Not Used
  2. Dose Reduction Ladder
    Starting dose: 300 mg, once daily, 4 × 75 mg 1ST REDUCTION: 225 mg, once daily, 4 × 75 mg 2ND REDUCTION: 150 mg, once daily, 3 × 75 mg NOT TOLERATED AT 150 MG => Stop, permanently discontinue
  3. CYP3A4 interactions with encorafenib
    Strong inhibitors (reduce to 75 mg or avoid) Posaconazole, voriconazole, itraconazole, ketoconazole Clarithromycin Ritonavir- or cobicistat-boosted regimens Moderate inhibitors (halve the dose or avoid) Fluconazole, erythromycin Diltiazem, verapamil Ciprofloxacin Aprepitant (3-day oral course) Strong inducers (avoid: may reduce efficacy) Rifampin, mitotane Carbamazepine, phenytoin Enzalutamide, apalutamide St John's wort
tosprivacy